new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure
September 2006
Experts are giving new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure.
Physicians already avoid giving rosiglitazone or pioglitazone (Actos) to patients with severe heart failure.
Now there's evidence that rosiglitazone increases cardiac risk in patients with LESS severe heart failure.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote